These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 6432400)
1. Ceftazidime disposition in acute and stable cystic fibrosis. Leeder JS; Spino M; Isles AF; Tesoro AM; Gold R; MacLeod SM Clin Pharmacol Ther; 1984 Sep; 36(3):355-62. PubMed ID: 6432400 [TBL] [Abstract][Full Text] [Related]
2. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Padoan R; Brienza A; Crossignani RM; Lodi G; Giunta A; Assael BM; Granata F; Passarella E; Vallaperta PA; Xerri L J Pediatr; 1983 Aug; 103(2):320-4. PubMed ID: 6348228 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis. Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670 [TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Blumer JL; Saiman L; Konstan MW; Melnick D Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Vinks AA; Touw DJ; Heijerman HG; Danhof M; de Leede GP; Bakker W Ther Drug Monit; 1994 Aug; 16(4):341-8. PubMed ID: 7974622 [TBL] [Abstract][Full Text] [Related]
6. Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Hedman A; Adan-Abdi Y; Alvan G; Strandvik B; Arvidsson A Clin Pharmacokinet; 1988 Jul; 15(1):57-65. PubMed ID: 3042246 [TBL] [Abstract][Full Text] [Related]
8. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. Strandvik B; Malmborg AS; Alfredson H; Ericsson A J Antimicrob Chemother; 1983 Jul; 12 Suppl A():283-7. PubMed ID: 6352633 [TBL] [Abstract][Full Text] [Related]
9. Serum and sputum concentrations of azlocillin, cefoperazone and ceftazidime in patients with cystic fibrosis. Martini N; Agostini M; Barlocco G; Bozzini L; Castellani L; Messori A; Scroccaro G; Mastella G J Clin Hosp Pharm; 1984 Dec; 9(4):303-9. PubMed ID: 6396321 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime. De Boeck K; Breysem L J Antimicrob Chemother; 1998 Mar; 41(3):407-9. PubMed ID: 9578170 [TBL] [Abstract][Full Text] [Related]
11. Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. Turner A; Pedler SJ; Carswell F; Spencer GR; Speller DC J Antimicrob Chemother; 1984 Nov; 14(5):521-7. PubMed ID: 6392281 [TBL] [Abstract][Full Text] [Related]
12. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. Permin H; Koch C; Høiby N; Christensen HO; Møller AF; Møller S J Antimicrob Chemother; 1983 Jul; 12 Suppl A():313-23. PubMed ID: 6352636 [TBL] [Abstract][Full Text] [Related]
13. Levofloxacin pharmacokinetics in adult cystic fibrosis. Lee CKK; Boyle MP; Diener-West M; Brass-Ernst L; Noschese M; Zeitlin PL Chest; 2007 Mar; 131(3):796-802. PubMed ID: 17356095 [TBL] [Abstract][Full Text] [Related]
14. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. Vinks AA; Brimicombe RW; Heijerman HG; Bakker W J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216 [TBL] [Abstract][Full Text] [Related]